Details

Autor(en) / Beteiligte

• Breithaupt, Mareile H.
• Krohmer, Evelyn
• Taylor, Lenka
• Körner, Eva
• Hoppe‐Tichy, Torsten
• Burhenne, Juergen
• Foerster, Kathrin I.
• Dachtler, Markus
• Huber, Gerald
• Venkatesh, Rakesh
• Eggenreich, Karin
• Czock, David
• Mikus, Gerd
• Blank, Antje
• Haefeli, Walter E.

Titel

Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers

Ist Teil von

• British journal of clinical pharmacology, 2023-08, Vol.89 (8), p.2458-2464

Ort / Verlag

England

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Aims In patients of all ages, metamizole is a frequently used analgesic. Recently, metamizole has been identified as an inducer of, among others, cytochrome P450 (CYP) 3A activity, but the time course of this interaction has not been evaluated. Methods Using repeated oral microdoses (30 μg) of the CYP3A index substrate midazolam, we assessed changes in midazolam pharmacokinetics (area under the concentration–time curve from 2–4 h: AUC2–4 and estimated partial metabolic clearance: eClmet) before, at steady‐state, and after discontinuation of 3 × 1000 mg metamizole/day orally for 8 days. Results Significant changes in pharmacokinetic parameters were detected already 3 days after start of metamizole treatment. At the steady‐state of enzyme induction, the geometric mean ratio of midazolam AUC2–4 was substantially reduced to 0.18 (90% confidence interval: 0.14–0.24) with a corresponding 5.43‐fold (4.15–7.10) increase of eClmet. After discontinuation of metamizole, the changes slowly recovered, but were still significant at the end of the observation period on the fifth day after discontinuation of metamizole therapy (AUC2–4 reduced to 0.50 [0.41–0.63] and eClmet 1.99‐fold increased [1.60–2.47, P < 0.05]). Conclusion Metamizole acts as a strong inducer of CYP3A already few days after start of metamizole administration and, thus, should be avoided in patients using drugs with narrow therapeutic index and major clearance via CYP3A. If their administration is essential, close monitoring and dose adjustment of comedication should be performed as early as the first week after the initiation and after discontinuation of metamizole therapy.